Emergent BioSolutions(US:EBS) Newsfilter·2025-03-03 21:23Core Insights - Emergent BioSolutions Inc. reported favorable full-year financial results for 2024, driven by core products and strategic stabilization actions [2][6][37] - The company aims to focus on profitable revenue growth and cash generation as part of its multi-year transformation plan [2][6] Financial Highlights - Q4 2024 total revenues were $194.7 million, a decrease of 30% compared to Q4 2023 [3][6] - Q4 2024 net loss was $31.3 million, a 37% improvement from a net loss of $49.5 million in Q4 2023 [3][6] - Adjusted EBITDA for Q4 2024 was $21.0 million, an increase of 518% from $3.4 million in Q4 2023 [3][6] - Full-year 2024 total revenues were $1.04 billion, a slight decrease of 1% from $1.05 billion in 2023 [4][6] Segment Performance - Commercial Products segment revenues decreased by 20% year-over-year to $398.9 million in 2024 [31][32] - MCM Products segment revenues increased by 14% year-over-year to $509.8 million in 2024 [33][35] - Services segment revenues increased by 34% year-over-year to $104.9 million in 2024 [36] Product Sales Breakdown - Q4 2024 product sales for NARCAN® decreased by 41% to $65.1 million compared to Q4 2023 [9][10] - Revenues from Anthrax MCM products decreased by 71% to $32.5 million in Q4 2024 [11] - Smallpox MCM revenues increased significantly by 565% to $76.5 million in Q4 2024 [12] Operating Expenses - Total operating expenses for Q4 2024 decreased by 36% to $204.2 million compared to Q4 2023 [17] - Research and development expenses decreased by 69% to $9.1 million in Q4 2024 [20] - Selling, general and administrative expenses decreased by 32% to $60.8 million in Q4 2024 [20] Future Guidance - The company forecasts total revenues for 2025 to be between $750 million and $850 million [38] - Adjusted EBITDA for 2025 is expected to be between $150 million and $200 million [38]